✦ LIBER ✦

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

✍ Scribed by Soini, E. J.; Hallinen, T. A.; Puolakka, K.; Vihervaara, V.; Kauppi, M. J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS19 COST-EFFECTIVENESS OF USING ETANER

✍ H Miadi-Fargier; B Fautrel; M Maravic; JP Daures; AL Ollivier; C Le Pen; F Maure 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

PMS21 COST—EFFECTIVENESS OF RITUXIMAB VS

✍ LA Bynum; N Joshi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Cost-Utility of First-Line Adalimumab an

✍ Soini, E.J.; Hallinen, T.; Vihervaara, V.; Kauppi, M.J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Cost effectiveness of adalimumab in the

✍ Bansback, N J 📂 Article 📅 2005 🏛 BMJ Publishing Group 🌐 English ⚖ 150 KB

PMS5 Benefit-Risk Analysis of Adalimumab

✍ K.A. Hicks; S.R. Earnshaw; J.W. Shaw; M. Cifaldi 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PMS54 COST-EFFECTIVENESS OF TOCILIZUMAB

✍ Diamantopoulos, A; Wintfeld, N; Giuliani, G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB